Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

NCT04160455 · tracked via the Priya Life Science France tracker

Sponsor

Centre Hospitalier Régional d'Orléans

Phase

Observational

Started

2019-11-07

Last updated

2025-12-30

Condition(s) studied

AutophagyGalectinsHIV InfectionsHighly Active Antiretroviral Therapy

Investigational drug(s) / intervention(s)

expression of a panel

expression of a panel: Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.

Study summary

Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area.

Our main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \<50 copies / ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: General criteria: * Age \>=18 years * Man or woman * Infected with HIV-1 (and not co-infected with HIV-2) * Followed at Orleans' Regional Hospital * Patient belonging to one of the predefined cohorts/groups (see below) * Patient having provided a written consent Specific profiles of HIV-infected patients for the ATGALIG-HIV study: Cohort A: patients on suppressive antiretroviral therapy (HIV RNA \<50 copies / ml for at least 4 years) initiated during the chronic phase, divided into 2 groups according to the following criteria: * group A1: CD4 count less than 500 cells / ml at the time of inclusion in the study * group A2: CD4 count above 500 cells / ml at the time of inclusion in the study Cohort B: patients on suppressive antiretroviral therapy (HIV RNA \<50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection) Cohort C: patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy, divided into the following 3 groups: * group C1: HIV diagnosis made during primary infection (within 4 months of infection) * group C2: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study * group C3: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study Cohort D: patients who have undetectable plasma HIV RNA (HIV RNA \<50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers) Exclusion Criteria: * Patient unable, according to the investigator, to meet the requirements of the protocol * Pregnant or lactating woman * Patient with a history of inflammatory bowel disease, malignancy, intestinal ischemia, malabsorption or other gastrointestinal dysfunction that, in the judgment of the investigator, could interfere with the interpretation of the results. * Presence of coagulation abnormality or unexplained bleeding history * Treatment with oral or injectable anticoagulant (curative or preventive) * Patient covered by Article L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code (including minors and protected adults) * Patient under guardianship or curatorship * Patient who uncovered by French health insurance Patient participating in another clinical trial, evaluating a treatment

Primary outcome measure(s)

Quantify of a panel of genes involved in autophagy on sub-populations — Quantifications will be done once for all patients (Day 0), except in cohort C where they will be repeated after they started antiretroviral therapy (at month 1, 3, 6, 12 and 24)
Quantify by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction
functional test on mononuclear cell subpopulations in the autophagy function — Quantifications will be done once for all patients (Day 0), except in cohort C where they will be repeated after they started antiretroviral therapy (at month 1, 3, 6, 12 and 24)
Evaluate on a functional test whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
Validation of the expression assays of genes involved in the autophagy function — Quantifications will be done once for all patients (Day 0), except in cohort C where they will be repeated after they started antiretroviral therapy (at month 1, 3, 6, 12 and 24)
Validate the expression assays of genes involved in the autophagy process and the statistical analyzes obtained on PBMCs on a validation cohort.

Trial sites (1)

Facility	City	Region	Status
CHU Orleans	Orléans	France	Recruiting

More Centre Hospitalier Régional d'Orléans trials in France

Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds Recruiting

Cohort Study on Medical Students' Mental Health Recruiting

Personalised Education Versus Usual Physiotherapy for Acute Rotator Cuff-Related Shoulder Pain Starting soon

Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. Recruiting

Blood'up Device Versus Manual Palpation for Arterial Puncture in Healthy Volunteers: A Pilot Randomized Study Under Normal and Simulated Hypotension Starting soon

Other trials for the same condition

Cohort IMEA 070 -Lenacapavir Compassional Active, not recruiting

Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV Recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults Active, not recruiting

Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities for Prevention Starting soon

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04160455 on ClinicalTrials.gov ↗ ← All trials in France